{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T17:27:29Z","timestamp":1794158849561,"version":"4.8.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"japan society for the promotion of science","doi-asserted-by":"publisher","award":["17K09017"],"award-info":[{"award-number":["17K09017"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s12185-021-03228-1","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T09:05:14Z","timestamp":1632906314000},"page":"77-86","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related\/unrelated allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1007","volume":"115","clinical-trial-number":[{"clinical-trial-number":"umin000023890","registry":"10.18810\/umin-japan"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4203-990X","authenticated-orcid":false,"given":"Hirohisa","family":"Nakamae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Nakane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asao","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutaka","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatomo","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Makuuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naonori","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruhito","family":"Takakuwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"key":"3228_CR1","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.3324\/haematol.2017.176107","volume":"102","author":"CJ Lee","year":"2017","unstructured":"Lee CJ, Savani BN, Mohty M, Labopin M, Ruggeri A, Schmid C, et al. Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102:1810\u201322.","journal-title":"Haematologica"},{"key":"3228_CR2","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","volume":"26","author":"A D'Souza","year":"2020","unstructured":"D\u2019Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, et al. Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2020;26:e177\u201382.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3228_CR3","doi-asserted-by":"publisher","first-page":"63574","DOI":"10.18632\/oncotarget.18862","volume":"8","author":"Z Gu","year":"2017","unstructured":"Gu Z, Wang L, Yuan L, Huang W, Li M, Guan L, et al. Similar outcomes after haploidentical transplantation with post-transplant cyclophosphamide versus HLA-matched transplantation: a meta-analysis of case-control studies. Oncotarget. 2017;8:63574\u201386.","journal-title":"Oncotarget"},{"key":"3228_CR4","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1182\/bloodadvances.2019000614","volume":"3","author":"MA Meybodi","year":"2019","unstructured":"Meybodi MA, Cao W, Luznik L, Bashey A, Zhang X, Romee R, et al. HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. Blood Adv. 2019;3:2581\u20135.","journal-title":"Blood Adv"},{"key":"3228_CR5","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1001\/jamaoncol.2019.3541","volume":"5","author":"N Gagelmann","year":"2019","unstructured":"Gagelmann N, Bacigalupo A, Rambaldi A, Hoelzer D, Halter J, Sanz J, et al. Haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy vs other donor transplantations in adults with hematologic cancers: a systematic review and meta-analysis. JAMA Oncol. 2019;5:1739\u201348.","journal-title":"JAMA Oncol"},{"key":"3228_CR6","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.bbmt.2019.07.028","volume":"25","author":"LJ Arcuri","year":"2019","unstructured":"Arcuri LJ, Mesquita Aguiar MT, Freitoso Ribeiro AA, Fonseca Pacheco AG. Haploidentical transplantation with post-transplant cyclophosphamide versus unrelated donor hematopoietic stem cell transplantation: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2019;25:2422\u201330.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3228_CR7","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.bbmt.2015.01.020","volume":"21","author":"KF Bradstock","year":"2015","unstructured":"Bradstock KF, Bilmon I, Kwan J, Micklethwaite K, Blyth E, Deren S, et al. Single-agent high-dose cyclophosphamide for graft-versus-host disease prophylaxis in human leukocyte antigen-matched reduced-intensity peripheral blood stem cell transplantation results in an unacceptably high rate of severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21:941\u20134.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3228_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ejh.12541","volume":"96","author":"U Holtick","year":"2016","unstructured":"Holtick U, Chemnitz JM, Shimabukuro-Vornhagen A, Theurich S, Chakupurakal G, Krause A, et al. OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. Eur J Haematol. 2016;96:27\u201335.","journal-title":"Eur J Haematol"},{"key":"3228_CR9","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.bbmt.2016.03.004","volume":"22","author":"IS Moiseev","year":"2016","unstructured":"Moiseev IS, Pirogova OV, Alyanski AL, Babenko EV, Gindina TL, Darskaya EI, et al. Graft-versus-host disease prophylaxis in unrelated peripheral blood stem cell transplantation with post transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil. Biol Blood Marrow Transplant. 2016;22:1037\u201342.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3228_CR10","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41409-018-0367-2","volume":"54","author":"MV Shah","year":"2019","unstructured":"Shah MV, Saliba RM, Rondon G, Chen J, Soebbing D, Rus I, et al. Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10\/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019;54:601\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"3228_CR11","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","volume":"6","author":"J Bola\u00f1os-Meade","year":"2019","unstructured":"Bola\u00f1os-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, et al. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019;6:e132\u201343.","journal-title":"Lancet Haematol"},{"key":"3228_CR12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.bbmt.2016.12.636","volume":"23","author":"F Carnevale-Schianca","year":"2017","unstructured":"Carnevale-Schianca F, Caravelli D, Gallo S, Coha V, D\u2019Ambrosio L, Vassallo E, et al. Post-transplant cyclophosphamide and tacrolimus-mycophenolate mofetil combination prevents graft-versus-host disease in allogeneic peripheral blood hematopoietic cell transplantation from HLA-matched donors. Biol Blood Marrow Transplant. 2017;23:459\u201366.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3228_CR13","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1182\/blood-2015-10-672071","volume":"127","author":"M Mielcarek","year":"2016","unstructured":"Mielcarek M, Furlong T, O\u2019Donnell PV, Storer BE, McCune JS, Storb R, et al. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood. 2016;127:1502\u20138.","journal-title":"Blood"},{"key":"3228_CR14","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3228_CR15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","volume":"18","author":"H Glucksberg","year":"1974","unstructured":"Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295\u2013304.","journal-title":"Transplantation"},{"key":"3228_CR16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21:389\u2013401.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3228_CR17","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","volume":"125","author":"SG Holtan","year":"2015","unstructured":"Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125:1333\u20138.","journal-title":"Blood"},{"key":"3228_CR18","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.exphem.2015.07.006","volume":"43","author":"H Nakamae","year":"2015","unstructured":"Nakamae H, Koh H, Katayama T, Nishimoto M, Hayashi Y, Nakashima Y, et al. HLA haploidentical peripheral blood stem cell transplantation using reduced dose of posttransplantation cyclophosphamide for poor-prognosis or refractory leukemia and myelodysplastic syndrome. Exp Hematol. 2015;43:921\u20139.","journal-title":"Exp Hematol"},{"key":"3228_CR19","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.bbmt.2015.06.008","volume":"21","author":"J Sugita","year":"2015","unstructured":"Sugita J, Kawashima N, Fujisaki T, Kakihana K, Ota S, Matsuo K, et al. Japan Study Group for Cell Therapy and Transplantation HLA-haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide after busulfan-containing reduced-intensity conditioning. Biol Blood Marrow Transplant. 2015;21:1646\u201352.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3228_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"3228_CR21","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/tri.13494","volume":"32","author":"H Nakamae","year":"2019","unstructured":"Nakamae H, Fujii K, Nanno S, Okamura H, Nakane T, Koh H, et al. A prospective observational study of immune reconstitution following transplantation with post-transplant reduced-dose cyclophosphamide from HLA-haploidentical donors. Transpl Int. 2019;32:1322\u201332.","journal-title":"Transpl Int"},{"key":"3228_CR22","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1182\/blood-2014-11-608406","volume":"125","author":"A Roberto","year":"2015","unstructured":"Roberto A, Castagna L, Zanon V, Bramanti S, Crocchiolo R, McLaren JE, et al. Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. Blood. 2015;125:2855\u201364.","journal-title":"Blood"},{"key":"3228_CR23","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1038\/bmt.2017.188","volume":"52","author":"M Martin","year":"2017","unstructured":"Martin M, Fornecker LM, Marcellin L, Mousseaux E, Hij A, Snowden JA, et al. Acute and fatal cardiotoxicity following high-dose cyclophosphamide in a patient undergoing autologous stem cell transplantation for systemic sclerosis despite satisfactory cardiopulmonary screening. Bone Marrow Transplant. 2017;52:1674\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"3228_CR24","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/j.bbmt.2012.06.019","volume":"18","author":"SR Solomon","year":"2012","unstructured":"Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant. 2012;18:1859\u201366.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"619","key":"3228_CR25","first-page":"e1","volume":"27","author":"A Pedraza","year":"2021","unstructured":"Pedraza A, Jorge S, Su\u00e1rez-Lled\u00f3 M, Pereira A, Guti\u00e9rrez-Garc\u00eda G, Fern\u00e1ndez-Avil\u00e9s F, et al. High-dose cyclophosphamide and tacrolimus as graft-versus-host disease prophylaxis for matched and mismatched unrelated donor transplantation. Transplant Cell Ther. 2021;27(619):e1-8.","journal-title":"Transplant Cell Ther"},{"key":"3228_CR26","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3390\/jcm10061173","volume":"10","author":"F Carnevale-Schianca","year":"2021","unstructured":"Carnevale-Schianca F, Caravelli D, Gallo S, Becco P, Paruzzo L, Poletto S, et al. Post-transplant cyclophosphamide and tacrolimus-mycophenolate mofetil combination governs GVHD and immunosuppression need, reducing late toxicities in allogeneic peripheral blood hematopoietic cell transplantation from HLA-matched donors. J Clin Med. 2021;10:1173.","journal-title":"J Clin Med"},{"key":"3228_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41409-018-0267-5","volume":"54","author":"PA Hagen","year":"2019","unstructured":"Hagen PA, Adams W, Smith S, Tsai S, Stiff P. Low mean post-transplantation tacrolimus levels in weeks 2\u20133 correlate with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation from related and unrelated donors. Bone Marrow Transplant. 2019;54:155\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"3228_CR28","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s12185-017-2341-y","volume":"107","author":"T Goto","year":"2018","unstructured":"Goto T, Tanaka T, Sawa M, Ueda Y, Ago H, Chiba S, et al. Prospective observational study on the first 51 cases of peripheral blood stem cell transplantation from unrelated donors in Japan. Int J Hematol. 2018;107:211\u201321.","journal-title":"Int J Hematol"}],"updated-by":[{"DOI":"10.1007\/s12185-021-03252-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000}}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03228-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-021-03228-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03228-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T12:04:58Z","timestamp":1642334698000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-021-03228-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["3228"],"URL":"https:\/\/doi.org\/10.1007\/s12185-021-03228-1","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12185-021-03252-1","asserted-by":"object"}]},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]},"assertion":[{"value":"2 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12185-021-03252-1","URL":"https:\/\/doi.org\/10.1007\/s12185-021-03252-1","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}